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We are pleased to provide an editorial to introduce this series
of articles on the achievements of the Global Programme to
Eliminate Lymphatic Filariasis (GPELF) over the last 2 decades.We
are delighted that so many of the major players in this journey
have agreed to contribute to this supplement, which tracks the
successes and identifies the challenges faced over 2 decades of
work as well as also looking towards the coming years.
The Royal Society of Tropical Medicine and Hygiene hosted the
launch meeting of the programme in January 2000 at its then
home, Manson House in London. Manson House was named af-
ter Sir Patrick Manson, who is regarded as the ‘father of trop-
ical medicine’ and was both a founding member and the first
president of the society. He discovered the early development
of Wuchereria bancrofti in Culex mosquitoes, which was the first
proven demonstration of the role that insects might play in the
transmission of pathogens. The proceedings of that meeting
were published in the Transactions of the Royal Society of Tropical
Medicine and Hygiene later that year (Molyneux et al 2000).1 It is
interesting to reflect how over what seems such a short time, the
science of filariasis has progressed, partnerships have flourished
and huge numbers of treatments have been delivered.
The latest figures for lymphatic filariasis (LF) reported byWorld
Health Organization (WHO) in theWeekly Epidemiological Record
of September 20202 stated that in 2019, 521million people were
treated, a figure for annual treatments that has been consis-
tent over the last decade, with a total of some 12 billion tablets
(albendazole, ivermectin and diethylcarbamazine [DEC]) deliv-
ered to countries since 2011. The cumulative total number of LF
treatments is estimated to be on the order of 7.7 billion since the
programme began.2 In this context, not only have 17 countries
been validated as having eliminated LF as a public health prob-
lem, many others have seen a dramatic decrease in prevalence
as rounds of mass drug administration have achieved scale and
high coverage rates.2
It is often forgotten that the broad-spectrum efficacy of the
drugs in the filariasis programme do not only impact filaria
parasitaemia, but also work against other infections in the ne-
glected tropical disease (NTD) portfolio, notably scabies and
soil-transmitted helminths. Indeed, it is not unreasonable to
claim the GPELF is the biggest deworming project of them all.
None of these achievements would have been possible with-
out the commitment of the whole LF community, as reflected by
the partnership cemented under the Global Alliance for the Elim-
ination of Lymphatic Filariasis (GAELF). This broad partnership
includes endemic countries, the WHO, non- governmental de-
velopment organizations (NGDOs), pharmaceutical and bilateral
donors, academic institutions and their research sponsors and
private philanthropy (notably the Bill and Melinda Gates Founda-
tion and the END Fund). Each of these partners brought together
their unique skills and expertise to ensure that the whole alliance
was greater than the constituent parts and forged GAELF into
a committed community that is still working to continually ad-
vance the goal of global elimination over the next 10 y, aligned
with our commitment to the WHO NTD Road Map.
The idea for a supplement to recognise the 20th anniversary of
the GPELF began in October 2019. This was made possible by the
generosity of our pharmaceutical partners with the assistance of
the Royal Society of Tropical Medicine and Hygiene, International
Health and Oxford University Press.
The topics of the papers and their authorship reflect the var-
ious critical themes of the many and diverse issues facing the
LF programme. It is appropriate to ‘begin at the beginning’ and
have for the record insights into the origins of the programme.We
then follow with a series of papers on the regional successes and
challenges, to clearly note the diversity of the epidemiology and
ecogeography of the disease. As our authors discuss, success-
ful LF interventions must be tailored to local settings, urban vs
rural, ecology of transmission, co-endemicity with onchocerci-
asis and loiasis, drug distribution modalities and cultural fac-
tors. As the saying goes, ‘one size does not fit all’—hence
the need for a regional perspective provided by authors who
have been directly involved with WHO in regional programme
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activities. The final papers cover broader topics such as eco-
nomics; the roles of communities, pharmaceutical companies,
NGDOs and IDA therapy (triple drug therapy); howmonitoring and
evaluation were undertaken and morbidity management and
disability prevention (MMDP). These are each authored by experts
who have been intimately involved in the programme for many
years. We are indebted to them for the time they have taken to
contribute to the supplement and for their individual contribu-
tions to what remains a highly successful global public health
endeavour.
The LF programme represents a major contribution to unlock-
ing the poverty cycle in many communities, seeks to leave no
one behind and is fully compatible with universal health cover-
age principles. Many millions of individuals are free of disability,
with the stigma that symptoms bring, and can be productive and
live more fulfilling lives without the burden this disease places
on families. Millions of disability-adjusted life years have been
averted (de Vlas et al 2016).3 It is the impact on people that is
the fundamental principle of this programme.
We hope our readers will find these papers to be an impor-
tant record of the achievements of the past 20 y while providing
a reminder of the challenges the final stages of the programme
will face, particularly as NTD programmes seek to overcome any
delays due to coronavirus disease 2019. The end game is always
the most difficult in any elimination or eradication programme,
with the emergence of the unexpected and resource challenges
brought to the fore. However, since the inception of the pro-
gramme, the LF community has been able to respond (exempli-
fied by the response to the earthquake in Haiti), limited access
due to insecurity [Yemen having been validated free of LF as a
public health problem] and the challenges of co-endemicity with
loiasis.
We again thank the authors for the time they have spent pro-
viding a rich source of information based on their unparalleled
experiences and themany reviewerswho have contributed to ad-
vise onmanuscripts. We trust you will enjoy this collection, which
we hope will be a reference point for several years to come.
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